| INTRODUCTION
Liver-related morbidity and mortality is rapidly expanding in people living with HIV, as a result of shared transmission modalities between HIV and hepatitis B (HBV) and C virus (HCV) as well as alcohol abuse, which is associated with HIV risk behaviours. 1 Over the past few decades, the consolidated use of combined antiretroviral therapy (cART) has dramatically changed the pattern of mortality of people living with HIV, where the proportion of deaths from opportunistic infections related to uncontrolled HIV replication has reduced in favour of chronic pathologies including cancer. 2 Hepatocellular carcinoma (HCC), the third most lethal malignancy, most frequently arises in the context of liver cirrhosis, a highly prevalent condition in patients co-infected with HIV and hepatitis. 3 Liver cirrhosis is not merely a predisposing factor but also a key prognostic determinant in patients with HCC, where impairment of liver reserve strongly influences treatment decisions. 4 The most widely adopted system to estimate hepatic impairment in HCC patients is the Child-Turcotte-Pugh classification, which combines objective biosynthetic parameters including circulating albumin, bilirubin and coagulation profile with more subjective prognostic traits including the presence and severity of ascites and encephalopathy. 5 While originally devised as a prognostic tool to estimate post-surgical mortality in cirrhotic patients without HCC, 6 the Child-Turcotte-Pugh classification has been subsequently incorporated as a biomarker of liver functional reserve in the vast majority of staging systems for HCC including the Barcelona Clinic Liver
Cancer (BCLC) algorithm, the Cancer of the Liver Italian prognostic (CLIP) score and many others. 7 Recent evidence has highlighted potential limitations in the prognostic accuracy of the Child-Turcotte-Pugh classification as a biomarker of liver function. On one hand, it has been argued that the clinical assessment of ascites and encephalopathy might suffer from lack of reproducibility between clinicians. 8 Second, the use of pre-determined cut-off values applied to laboratory variables might artificially reduce the ability to capture more subtle changes in liver function that may be of prognostic significance. 9 To overcome these limitations, which can influence optimal treatment allocation in patients with HCC, a novel marker of liver functional reserve based exclusively on circulating albumin and bilirubin levels, the albumin-bilirubin (ALBI) grade, has been proposed as an alternative to the Child-Turcotte-Pugh class. 10 Originally derived from large cohorts of HCC patients and cirrhotic controls, the albumin-bilirubin grade has subsequently been validated in patients of diverse geographical origin and aetiology of chronic liver disease [11] [12] [13] [14] and integrated with currently available prognostic algorithms in HCC. 15, 16 However, there is no evidence to support the clinical utility of the albumin-bilirubin grade in patients diagnosed with HIV-associated HCC, a patient population where the progression of liver fibrosis is characterised by an accelerated course. 17 The aim of this study was therefore to independently validate the prognostic value of the albumin-bilirubin grade in the setting of a large collaborative study including patients with HIV-associated HCC derived from Liver Cancer in HIV study cohort.
| PATIENTS AND METHODS
This retrospective study identified all patients diagnosed with HCC on a background of HIV infection in 44 referral centres providing specialist multidisciplinary care for HIV and HCC across nine countries including USA, Canada, Brazil, Argentina, Germany, Spain, UK, Italy and Australia (Table S1 ). Consecutive referrals in the period between 1992 and 2016 were collected in a joint database as part of an international research consortium using electronic case report forms. Methodology of data collection and clinical outcomes pertaining to a proportion of the patients was published in 2007. 18 All patients had a diagnosis of HCC either on imaging or by histological criteria according to international guidelines. 19 To avoid incurring in the confounding effect stemming from a fully restored liver function in the prognosis of transplant recipients, patients who underwent liver transplantation were excluded (n = 33), leaving a total of 387 patients eligible for analysis.
Medical records at each participating institution were searched to derive complete demographic, staging and treatment data. All the clinical variables were obtained at baseline, defined as the time of HCC diagnosis. HCC staging followed computerised tomography and/or magnetic resonance imaging criteria as clinically required to derive extent of intra and extra-hepatic spread. Computation of the Child-Turcotte-Pugh functional class and BCLC stage followed standard pre-published methodology. 20 The albumin-bilirubin grade was calculated using the following equation: linear predictor = (log 10 bilirubin 9 0.66) + (albumin 9 À0.085), where bilirubin is in lmol/L and albumin in g/L. The continuous linear predictor was further categorised into three different grades for prognostic stratification purposes: grade 1 (inferior to À2.60), grade 2 (between À2.60 and À1.39) and grade 3 (above À1.39) as previously described. 10 The primary clinical endpoint of the study was overall survival (OS), calculated from the date of diagnosis to patients' death and/or last follow-up. The majority of patients were on cART (n = 322, 83%) with a median duration of treatment of 8.8 years prior to the diagnosis of HCC. Most patients had undetectable HIV viral load at the time of HCC diagnosis (n = 240, 65%) and CD4 counts >200 cells/mm 3 (n = 265, 69%). The most prevalent risk factor for HIV infection was intravenous drug use (n = 211, 55%).
| Statistical analysis

| The prognostic performance of the albuminbilirubin grade in HIV-associated HCC
The ability of the albumin-bilirubin grade to stratify patients according to OS amongst all patients (n = 387) is shown in Figure 1 . The median OS in patients with albumin-bilirubin grade 1 (n = 64, 17%) was 97 months (95% CI 13-180 months) compared to 17 months (95% CI 11-22 months) of albumin-bilirubin grade 2 (n = 182, 48%) and 6 months (95% CI 4-9 months), of albumin-bilirubin grade 3 patients (n = 141, 35% P < .001). Hazard ratios for mortality considering albumin-bilirubin grade 1 as reference prognostic category was 2.0 (95% CI 1.3-3.3, P = .002) for albumin-bilirubin grade 2 and 4.7
(95% CI 2.3-7.5, P < .001) for albumin-bilirubin grade 3 ( Figure 1A ).
When stratified according to Child-Turcotte-Pugh class, OS worsened from 27 months (95% CI 14-40) in patients within func- HBV DNA levels (n = 39, median OS not reached, 27 months and 10 months for grade 1, 2 and 3, log rank P = .005).
| DISCUSSION
The incidence of HCC is seven times higher in PLHIV compared to the general population. 23 Despite progressive improvements in the multidisciplinary management of both HIV infection and liver cancer, the burden of HCC has been steadily increasing, having seen a 23-fold prevalence rise in HCV-co-infected patients over the past 20 years. 24 This has been unfortunately mirrored by a consensual increase in mortality, where HCC now accounts as a leading cause of death in this patient group, being responsible for up to 40% of liver-related events. 25 The tumour-promoting properties of HIV exist by virtue of a synergistic oncogenic effect with hepatitis mediated by a faster progression of fibrosis in the context of immune-depression, 26 which can be further exacerbated by other co-existing noxae including alcohol consumption, cART-induced hepatotoxicity and the presence of an underlying metabolic syndrome. 27 All these factors might not just shape the risk of HCC, but also have a direct impact on the tumour microenvironment once HCC is diagnosed, imposing an additional toll on residual liver function compared to HIV-negative patients. Building on our observation in large cohorts of patients with HCC of various aetiology and stage, 13 we designed this large, collaborative, study to verify whether the prognostic role of the albuminbilirubin grade, a novel biomarker of liver function, might extend to patients with concurrent HIV infection, where HCC has been often depicted as carrying a more adverse clinical course. It is conceivable that the relatively wide recruitment times that characterise our patient cohort might have influenced patients' survival. However, the median OS reported according to BCLC stage and type of treatment reflect survival rates reported in clinical guidelines. 37 Furthermore, in our study, we verified the value of a number of prognostic factors indicative of tumour burden, liver function and HIV infection, confirming a close similarity to previously published patient cohorts, 27 to suggest our patient sample to be fully representative of the entire population of HIV-associated HCC. The retrospective design should also be acknowledged as a limitation to our work. However, this study is-to our knowledge-the largest to report survival outcomes in HIV-associated HCC, where the multi-centre accrual of consecutive, unselected referrals limits the chances of systematic bias.
In conclusion, this study supports the role of the albumin-biliru- and is able to reflect hepatocellular damage relating to HIV-related immune dysfunction and active HIV replication, establishing an appealing prognostic relationship between the control of HIV infection and progressive liver dysfunction in patients with cirrhosis and superimposed HCC.
Due to its robust pathophysiological foundations and optimal stratifying features, the albumin-bilirubin grade deserves verification as a novel prognostic biomarker in prospective clinical studies in a view to potentially incorporate it in routine clinical practice.
